CD274 and metastatic malignant neoplasm: After the Food and Drug Administration (FDA) approval of PD-L1 inhibitors for treatment of microsatellite instable and metastatic cancers in several types of malignancies including EC [12,13,14,15,16], this promising therapeutic modality has been the encouraging force behind the exploration of PD-L1 expression in EC in several recent reports [17,18,19,20,21,22].